Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
888 studies found for:    IL13
Show Display Options
Rank Status Study
1 Terminated An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
Conditions: Brain Neoplasm;   Glioma
Intervention: Drug: IL13-PE38QQR
2 Withdrawn Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma
Condition: Recurrent Malignant Glioma
Intervention: Drug: IL13-PE38QQR
3 Not yet recruiting Validation of an Allergic Rhinitis Control Test in Teenagers
Condition: Allergic Rhinitis
Intervention: Other: Self questionnaire for allergic rhinitis control
4 Completed Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Mixed Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
5 Completed Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Mixed Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
6 Terminated Possible New Therapy for Advanced Cancer
Condition: Adrenocortical Carcinoma
Intervention: Drug: IL-13-PE
7 Completed Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Mixed Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
8 Completed Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
Conditions: Malignant Glioma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Mixed Oligoastrocytoma;   Malignant Astrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: targeted fusion protein therapy;   Procedure: surgery
9 Withdrawn Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: cintredekin besudotox;   Procedure: conventional surgery
10 Completed IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
Conditions: Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Oligoastrocytoma
Interventions: Drug: IL13-PE38QQR;   Procedure: Surgery for placement;   Procedure: Radiation therapy;   Drug: Temozolomide with radiation therapy
11 Completed The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Drug: IL13-PE38QQR;   Procedure: surgery and catheter placement (2 procedures);   Drug: prolifespan 20 with carmustine implant (GLIADEL® Wafer);   Procedure: surgery and wafer placement (1 procedure)
12 Completed Sensitivity and Specificity of Nasal Provocation Test in Allergic Rhinitis to House Dust Mites
Condition: Allergic Rhinitis
Intervention: Other: Nasal provocation test
13 Completed Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)
Condition: Allergic Rhinitis Due to Grass Pollen
Intervention: Other: Allergic rhinitis
14 Completed Study to Investigate Effects of CAL-263 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber
Condition: Allergic Rhinitis
Interventions: Drug: CAL-263;   Drug: Placebo
15 Completed Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis
Condition: Allergic Rhinitis
Intervention: Drug: Levocetirizine oral solution
16 Completed Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis
Conditions: Asthma;   Allergic Rhinitis
Interventions: Drug: Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo;   Drug: Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase;   Drug: QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo;   Drug: QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris;   Drug: Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase;   Drug: Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
17 Completed Comparison of Effectiveness and Safety of Sublingual Immunotherapy in Children With Allergic Rhinitis
Condition: Allergic Rhinitis
Interventions: Biological: sublingual allergen extract;   Biological: placebo
18 Completed Anti-inflammatory H1 Antihistamines Allergic Rhinitis
Condition: Allergic Rhinitis
Interventions: Drug: Levocetirizine;   Drug: Desloratadine
19 Completed
Has Results
Herbal Treatment for Perennial Allergic Rhinitis
Condition: Perennial Allergic Rhinitis
Interventions: Drug: Shi-Bi-Lin;   Other: Placebo
20 Completed The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis
Condition: Allergic Rhinitis
Interventions: Drug: PF-03654764;   Drug: Allegra;   Drug: Allegra-D;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.